Last updated on November 2019

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer


Brief description of study

This is a combination Phase I and Phase II study, with an aim to evaluate the combination of GSK525762 and fulvestrant in women with HR+/HER2- advanced or metastatic breast cancer, who have disease that has progressed after prior treatment with at least one line of endocrine therapy.

The objectives of the study are to first identify, in open-label single-arm Phase I, a recommended Phase II dose of GSK525762 that may be combined safely with fulvestrant. Phase I will follow a modified toxicity probability interval (mTPI) design, and a sentinel group will be evaluated first for dose-limiting toxicity and further expanded to collect additional safety data. This will be followed by a double-blind, randomized controlled Phase II, to identify the clinical activity of the two study treatments when given in combination. The composition of Phase II will be selected at the end of Phase I.

Approximately, up to 140 subjects and 154 subjects will receive study treatment in Phase I and Phase II respectively. A completed subject will be one who is followed until death.

Clinical Study Identifier: NCT02964507

Find a site near you

Start Over

GSK Investigational Site

Birmingham, AL United States
  Connect »

GSK Investigational Site

Scottsdale, AZ United States
  Connect »

GSK Investigational Site

Jacksonville, FL United States
  Connect »

GSK Investigational Site

Tamarac, FL United States
  Connect »

GSK Investigational Site

Augusta, GA United States
  Connect »

GSK Investigational Site

Chicago, IL United States
  Connect »

GSK Investigational Site

New Orleans, LA United States
  Connect »

GSK Investigational Site

Boston, MA United States
  Connect »

GSK Investigational Site

Rochester, MN United States
  Connect »

GSK Investigational Site

Kansas City, MO United States
  Connect »

GSK Investigational Site

Saint Louis, MO United States
  Connect »

GSK Investigational Site

Bronx, NY United States
  Connect »

GSK Investigational Site

White Plains, NY United States
  Connect »

GSK Investigational Site

Providence, RI United States
  Connect »

GSK Investigational Site

Dallas, TX United States
  Connect »

GSK Investigational Site

Houston, TX United States
  Connect »

GSK Investigational Site

San Antonio, TX United States
  Connect »

GSK Investigational Site

Fairfax, VA United States
  Connect »

GSK Investigational Site

Seattle, WA United States
  Connect »

GSK Investigational Site

Port Macquarie, Australia
  Connect »

GSK Investigational Site

Bedford Park, Australia
  Connect »

GSK Investigational Site

Saint-Herblain cedex, France
  Connect »

GSK Investigational Site

Gyeonggi-do, Korea, Republic of
  Connect »

GSK Investigational Site

Seoul, Korea, Republic of
  Connect »

GSK Investigational Site

Manchester, United Kingdom
  Connect »

GSK Investigational Site

Northwood, United Kingdom
  Connect »

GSK Investigational Site

Nottingham, United Kingdom
  Connect »

GSK Investigational Site

Glasgow, United Kingdom
  Connect »